Dive in
We have our own point of view on the people, technologies, and conversations that will shape the future.
Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.
For those in healthcare, JPM provides the unofficial kickoff to every new year with a chance to recap the year before and inform our view on the year ahead.
Drug design is both a natural fit and a unique challenge for generative AI, given large but messy datasets, time and cost of real-world testing, and the complexity of human trials.
Genesis Therapeutics is pioneering AI technologies to create medicines for patients with severe and unmet medical needs.
Delfi Diagnostics has developed a test that combines ultra-low-cost sequencing and machine learning to detect cancer early.
Recursion is a breakthrough drug discovery company that combines a novel computer vision platform with deep disease biology and chemistry.
